<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00380172</url>
  </required_header>
  <id_info>
    <org_study_id>AMD-03-02</org_study_id>
    <nct_id>NCT00380172</nct_id>
  </id_info>
  <brief_title>Long-Term Efficacy in AMD of Rheopheresis in North America</brief_title>
  <official_title>A Multicenter, Open Label, Prospective Study to Determine Safety and Efficacy Over an Additional 12-Month Period With Non-Exudative Age-Related Macular Degeneration (With Follow-on to 12-Months)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OccuLogix</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>OccuLogix</source>
  <brief_summary>
    <textblock>
      The purpose of these studies are to evaluate the effect on vision in subjects with AMD who
      received active and placebo treatment in the MIRA-1 study.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>October 2005</start_date>
  <completion_date>October 2007</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary objective of this study is to evaluate the change from baseline and ETDRS visual acuity in subjects with non-exudative AMD who participated in AMD-02-99.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>The secondary objective of this study is to evaluate the safety of rheopheresis filtration treatments in subjects with non-exudative AMD as measured by AE's early DC's and Lab evaluations.</measure>
  </secondary_outcome>
  <enrollment>120</enrollment>
  <condition>Macular Degeneration</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Rheopheresis blood filtration</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must have participated in treatment arm of MIRA-1 trial and completed 4 treatments and
             6 and 9 month follow up visits.

          -  Dry AMD in at least one eye.

          -  Available for study duration of 12 months.

          -  Weigh &gt;110 lbs.

          -  If on lipid-lowering medication must remain on for duration of trial. If not, must
             agree to not initate during trial.

          -  Normal Pt/ PTT. If on coumadin, at the discretion of the investigator.

          -  Must be highly motivated, alert and oriented, and able to provide consent.

          -  Agree to discontinue current ocular vitamin regimen and take uniform supplement
             provided by the sponsor.

        Exclusion Criteria:

          -  Both eyes wet AMD.

          -  Condition limiting view of the fundus.

          -  Poor general health or unstable diseases.

          -  HCT &lt; 35%, evidence of active bleeding, platelet count &lt;100000 K/uL, prolonged Pt/
             PTT, or significant coagupapathies.

          -  significant cardiac problems.

          -  Uncontrolled hypertension.

          -  History of CVA of TIA within a year.

          -  Significant hepatic, renal, or pulmonary disease, or insulin dependent diabetes.

          -  Allergy to fluorescein sodium and indocyanine green (ICG), heparin, ACDA, local
             anesthetics, or adhesive tape.

          -  Pregnant or breastfeeding women, or women of childbearing potential not using chemical
             or mechanical contraception.

          -  Investigation trial within 30 days.

          -  Major surgery within 30 days.

          -  Unwilling to adhere to visit schedule.

          -  Unstable medical of psychological condition.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nozhat Choudry`, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>OccuLogix, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Retina Vitreous Associates</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aran Eye Associates</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Health Care</name>
      <address>
        <city>Ft. Myers</city>
        <state>Florida</state>
        <zip>33901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Macula Center</name>
      <address>
        <city>Palm Harbor</city>
        <state>Florida</state>
        <zip>34684</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UIC Eye Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Macula Care</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolina Eye Associates</name>
      <address>
        <city>Southern Pines</city>
        <state>North Carolina</state>
        <zip>28387</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Associated Retinal Consultants</name>
      <address>
        <city>Bala Cynwyd</city>
        <state>Pennsylvania</state>
        <zip>19004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>W. Bradley Kates, MD</name>
      <address>
        <city>Oakville,</city>
        <state>Ontario</state>
        <zip>L6H 3P1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 21, 2006</study_first_submitted>
  <study_first_submitted_qc>September 21, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 25, 2006</study_first_posted>
  <last_update_submitted>September 21, 2006</last_update_submitted>
  <last_update_submitted_qc>September 21, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 25, 2006</last_update_posted>
  <keyword>AMD</keyword>
  <keyword>Macular Degeneration</keyword>
  <keyword>Retinal Degeneration</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

